Welcome a new era of therapeutic development in which natural compounds can be leveraged to accelerate the delivery of breakthrough medical solutions.
Our mission is to improve patient outcomes by advancing therapy for critical illness.
Andira is a privately held health science firm, leveraging natural compounds to accelerate the delivery of urgently-needed solutions for antibiotic-resistant infections and metastatic cancer.
Andira is home to:
Novel Pharmacotherapeutic Platform
Applying proven innovation to generate a consistent stream of technologies that address highly prevalent medical conditions
Therapeutic and Medical Device Products
Following established regulatory pathways to achieve product approvals
An Industry-Leading Team
A proven track record of pharmaceutical commercialization success through execution of viable scientific, clinical and regulatory strategies
Therapeutic
Development
Programs
Dermatology
Our novel, Matrix3 triple synergy formula provides faster onset and improved efficacy against drug-resistant bacteria including MRSA and Pseudomonas.
Hospital Acquired Infections
Our Hospital Infections program is advancing an injectable product for Drug-Resistant Enterococcus (“VRE”) – a life-threatening hospital-acquired infection.
Oncology
Andira uses the most translational research techniques available to optimize treatments to address Metastatic Breast Cancer.
COMPANY NEWS AND EVENTS
Latest News
Andira Recognizes the Outstanding Achievements of Research Scientist Claudia Helena Dietrich, DDS, MSc, PhD
Andira CEO Dana Lambert, PhD says, “I wanted to take the opportunity to recognize Dr. Claudia Dietrich and her outstanding achievements as a research scientist on our team. She
Andira Pharmaceuticals Hires Eurofins Discovery to Further Develop Lead Asset
VANCOUVER, BC, May 31, 2022 – Andira Pharmaceuticals is proud to announce the hiring of Eurofins Discovery to conduct pre-clinical research on Andira’s lead asset, a cannabinoid-based injectable antibiotic
